16-23607924-GGGTT-GTCATTAAC
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_024675.4(PALB2):c.3286_3289delAACCinsGTTAATGA(p.Asn1096ValfsTer4) variant causes a frameshift, missense change. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. N1096N) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_024675.4 frameshift, missense
Scores
Clinical Significance
Conservation
Publications
- hereditary breast carcinomaInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen, Ambry Genetics
- Fanconi anemia complementation group NInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
- pancreatic cancer, susceptibility to, 3Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- familial ovarian cancerInheritance: AD Classification: MODERATE Submitted by: ClinGen
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary nonpolyposis colon cancerInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| PALB2 | NM_024675.4 | c.3286_3289delAACCinsGTTAATGA | p.Asn1096ValfsTer4 | frameshift_variant, missense_variant | Exon 12 of 13 | ENST00000261584.9 | NP_078951.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| PALB2 | ENST00000261584.9 | c.3286_3289delAACCinsGTTAATGA | p.Asn1096ValfsTer4 | frameshift_variant, missense_variant | Exon 12 of 13 | 1 | NM_024675.4 | ENSP00000261584.4 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Familial cancer of breast Pathogenic:3
This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.
This sequence change creates a premature translational stop signal (p.Asn1096Valfs*4) in the PALB2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PALB2 are known to be pathogenic (PMID: 17200668, 17200671, 17200672, 24136930, 25099575). Information on the frequency of this variant in the gnomAD database is not available, as this variant may be reported differently in the database. This variant has not been reported in the literature in individuals affected with PALB2-related conditions. Studies have shown that this premature translational stop signal is associated with inconclusive levels of altered splicing (internal data). For these reasons, this variant has been classified as Pathogenic.
not provided Pathogenic:2
This variant alters the translational reading frame of the PALB2 mRNA and causes the premature termination of PALB2 protein synthesis. In the published literature, this variant has been reported in an individual with an individual with a hereditary breast and ovarian cancer (HBOC) syndrome related disorder (PMID: 24763289 (2014)). This variant has not been reported in large, multi-ethnic general populations (Genome Aggregation Database, http://gnomad.broadinstitute.org). Based on the available information, this variant is classified as pathogenic.
Reported in the literature in individuals referred for hereditary cancer testing (PMID: 24763289); Frameshift variant predicted to result in protein truncation in a gene for which loss of function is a known mechanism of disease; Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 24485656, 19609323, 20871615, 24763289)
Hereditary cancer-predisposing syndrome Pathogenic:2
The c.3286_3289delAACCinsGTTAATGA pathogenic mutation, located in coding exon 12 of the PALB2 gene, results from the deletion of 4 nucleotides and insertion of 8 nucleotides causing a translational frameshift with a predicted alternate stop codon (p.N1096Vfs*4). This alteration occurs at the 3' terminus of thePALB2 gene, is not expected to trigger nonsense-mediated mRNA decay, and impacts the last 7.7% of the protein. However, premature stop codons are typically deleterious in nature, the impacted region is critical for protein function, and a significant portion of the protein is affected (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this variant is interpreted as a disease-causing mutation.
This variant causes a replacement of 4 nucleotides at c.3286_3289 positions in exon 12 of the PALB2 gene with GTTAATGA, creating a frameshift and premature translation stop signal. This variant is expected to truncate the carboxyl terminus of the protein that functions in BRCA2 and RAD-51 interactions (PMID: 25833843) and may trigger nonsense-mediated decay. This variant is expected to result in an absent or non-functional protein product. To our knowledge, functional studies have not been reported for this variant nor has this variant been reported in individuals affected with hereditary cancer in the literature. **However, other truncations at the carboxyl terminus of PALB2 after the position of this variant have been reported in at least 20 individuals and families affected breast and/or ovarian cancer (PMID: 17200668, 25099575, 25452441, 26315354, 28281021) and in compound heterozygous carriers affected with Fanconi anemia (PMID: 17200671).** This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of PALB2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Hereditary breast ovarian cancer syndrome Pathogenic:1
Variant summary: PALB2 c.3286_3289delinsGTTAATGA (p.Asn1096ValfsX4) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251488 control chromosomes. c.3286_3289delinsGTTAATGA has been reported in the literature in individuals affected with Hereditary Breast And Ovarian Cancer Syndrome (LaDuca_2014). This report does not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at